(2R,3R,4R,5S,6R)-3,4,5,6-Tetraacetoxy-tetrahydro-pyran-2-carboxylic acid | 104195-04-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R,3R,4R,5S,6R)-3,4,5,6-Tetraacetoxy-tetrahydro-pyran-2-carboxylic acid
• 英文别名: (2R,3R,4R,5S,6R)-3,4,5,6-tetraacetyloxyoxane-2-carboxylic acid
• CAS: 104195-04-2
• 化学式: C₁₄H₁₈O₁₁
• 分子量: 362.29
• InChiKey: FHWVABAZBHDMEY-SSKLVLDBSA-N

物化性质

• 沸点：
  458.3±45.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  152
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R,5S,6R)-3,4,5,6-Tetraacetoxy-tetrahydro-pyran-2-carboxylic acid 在 sodium hydroxide 、 IR-120 acidic ion-exchange resin 作用下， 以 乙醚 、 水 为溶剂， 反应 2.5h， 生成 galacturonic acid
  参考文献：
  名称：

  Interactivity of chiral catalysts and chiral auxiliaries in the cycloaddition of activated dienes with aldehydes: a synthesis of L-glucose

  摘要：

  DOI：

  10.1021/ja00282a035
• 作为产物：
  描述：

  (2S,3R,4S)-3,4-二乙酰氧基-2-苯基-4H(2,3)-二氢吡喃 在 4-二甲氨基吡啶 N-morpholine oxide 、 四氧化锇 、 双氧水 、 臭氧 、 三乙胺 作用下， 反应 90.0h， 生成 (2R,3R,4R,5S,6R)-3,4,5,6-Tetraacetoxy-tetrahydro-pyran-2-carboxylic acid
  参考文献：
  名称：

  Interactivity of chiral catalysts and chiral auxiliaries in the cycloaddition of activated dienes with aldehydes: a synthesis of L-glucose

  摘要：

  DOI：

  10.1021/ja00282a035

文献信息

• Regulation of microglia polarization <i>via</i> mannose receptor-mediated delivery of siRNA by ligand-functionalized DoGo LNP
  作者：Hai Xiao、Shuqin Han、Huricha Baigude

  DOI：10.1039/d1ra04293a

  日期：——

  Mannose functionalized DoGo lipid nanoparticles (denote M3) can effectively deliver siRNA to microglia via receptor-mediated internalization, knockdown target gene and induce neuroprotective M2 polarization.

  曼诺糖功能化的DoGo脂质纳米粒子（称为M3）可以通过受体介导的内吞作用，有效地将siRNA传递给小胶质细胞，击倒目标基因并诱导神经保护性的M2极化。
• Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US10953027B2

  公开（公告）日：2021-03-23

  Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

  本文公开了活性剂、含有活性剂的组合物、含有活性剂的单位剂型以及活性剂的使用方法，例如用于治疗代谢紊乱或非酒精性脂肪肝或调节代谢标志物或非酒精性脂肪肝标志物。
• Acylated active agents and methods of their use for the treatment of autoimmune disorders
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US11058698B2

  公开（公告）日：2021-07-13

  Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

  本文公开了酰化活性剂及其使用方法，例如用于调节自身免疫标记物或治疗自身免疫性疾病的方法。
• ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US20200188418A1

  公开（公告）日：2020-06-18

  Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
• ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US20210177877A1

  公开（公告）日：2021-06-17

  Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.